Major HER2+ breast cancer trial identifies factors associated with pathologic complete response to less intensive chemotherapy
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Oct-2026 11:17 ET (23-Oct-2026 15:17 GMT/UTC)
Results from ECOG-ACRIN’s CompassHER2-pCR trial identify clinical and molecular predictors of pathologic complete response (pCR) after 12 weeks of THP, a less intensive neoadjuvant regimen combining one chemotherapy drug with two HER2-targeted drugs. It is the largest prospective trial of this approach in stage II-IIIA HER2+ breast cancer. Follow-up is ongoing to assess 3-year recurrence-free survival among patients who had a pCR. Published in JCO, the findings will be featured in a podcast.
The Mount Sinai Tisch Cancer Center has brought its electronic health record (EHR)-to-electronic data capture (EDC) technology into routine use across its cancer research program. Powered by IgniteData’s Archer platform and integrated with Epic, the technology has produced early results, reducing clinical trial data-entry time by more than half while improving the efficiency and reliability of research data collection.